Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Curr Opin Endocrinol Diabetes Obes. 2016 Jun;23(3):233–241. doi: 10.1097/MED.0000000000000247

Table 3.

Cytotoxic chemotherapy in advanced ACC

Study Regimen Number of
Evaluable
patients		 Obje
ctive
resp
onse
(%)		 Response
duration
(median, mo)		 Median
surviva
l(mo)
Bukowski (29)

Phase II		 Cisplatin/Mitotane 37 30 7.9 11.8
Berruti (27)

Phase II		 EDP-M 28 53.5 24.4 (TTP in
responding
pts)		 NR
Khan (20)

Phase II		 Sz-M 23 * 34.8 NR 16**
Williamson

Phase II(30)		 Cisplatin/VP16->
Mitotane at disease
progression		 45 11 NR 10
Abraham (31)

Phase II		 Doxorubicin/VP16/Vincris
tine/Mitotane		 35 22† 12.4 (mean) 13.5
Sperone (32)

Phase II		 Gemcitabine/metronomic
5FU or Cape		 28 7.1 5.3 (TTP) 9.8
Fassnacht (28)

Phase III		 EDP-M v Sz-M 304

151 (EDP-
M)

153 (Sz-
M)		 23.2
v 9.2

(p<0.001)		 5 v 2.1(PFS)

(p<0.001)		 14.8 v
12

(p 0.07)
*

11 patients underwent radical surgery and received Sz-M on recurrence or when they developed metastatic disease, 12 patients had recurrent/metastatic disease at diagnosis;

**

in patients with advanced disease at diagnosis;

†

includes minor responses; TTP=time to progression; mo=months